New guidance expands treatment options for eligible patients
News
AstraZeneca’s Forxiga recommended for chronic kidney disease treatment
Updated guidance from NICE expands eligibility for dapagliflozin us
Lumanity and Parker Institute partner to support delivery of new immunotherapies
The alliance combines Lumanity’s commercial and development strategy capabilities with PICI’s translational research expertise
TQ Therapeutics acquires Juno GmbH to support decentralised cell therapy platform
TQ Therapeutics (TQx) has acquired Juno Therapeutics GmbH, the German subsidiary of Juno Therapeutics, through a share...
Eli Lilly acquires SiteOne Therapeutics to advance treatment for chronic pain
Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid...
NICE recommends sparsentan for IgA nephropathy
First non-immunosuppressive dual-action therapy approved for eligible patients
Oxford Brain Diagnostics to launch groundbreaking dementia diagnosis technology
Company secures regulatory approvals for commercial rollout in UK and US
MHRA Board meets in Scotland for first time, reinforcing UK-wide health priorities
The Board of the Medicines and Healthcare products Regulatory Agency (MHRA) has met in Scotland for the first time,...
Sonrai and AOA Dx partner to accelerate ovarian cancer test development
Strategic collaboration aims to improve early diagnosis
Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia
The drug was recently approved in the US for familial chylomicronaemia syndrome
FDA approves Amneal’s self-administered migraine drug Brekiya
Brekiya is now the first DHE auto-injector to be approved by the regulator
MHRA approves guselkumab for Crohn’s disease and ulcerative colitis
Regulator confirms safety and efficacy of new treatment option for patient
Massalia Therapeutics launches to advance novel treatments for complex conditions
Biotech spin-off targets fibrosis, neoplasm and neovascularization
AviadoBio opens UK trial for FTD gene therapy
Aspire-FTD study aims to stop disease progression with one-time treatment
Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease
Trial progresses towards topline data expected later in the year
